The President of the European Parliament says Germany should seek a deal with the Trump administration to resolve their trade dispute around drug pricing, Politico reports

Drug pricing disputes between Washington and European capitals have a long track record, and episodes of this kind have historically been resolved through negotiated frameworks rather than tariff escalation, which is why signals from senior European institutions about seeking a deal tend to matter more than the rhetoric of individual officials. The actors matter here: the European Parliament presidency is a convening and agenda-setting role rather than a negotiating one, so the statement is directional rather than a mandate, and the precedent in comparable trade spats is that formal talks run through the Commission and member-state trade ministers. The distinction worth drawing is between pharma pricing and the broader tariff agenda: drug pricing disputes have often been ring-fenced from wider goods trade conflicts, so a resolution here does not automatically carry over to sectors like autos or agriculture that have historically been the sticking points. Worth watching is whether Berlin or Brussels picks up the suggestion formally, and whether the US administration engages on a narrow pharma track or folds it into a wider negotiation. As reported comment rather than a policy move, the read is that the channel is diplomatic positioning, not yet a changed trade regime.